Compounds > benzylguanidine
Page last updated: 2024-11-05

benzylguanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzylguanidine is a small molecule that has been studied for its potential use in various applications, including drug development. It is synthesized through a straightforward reaction of benzyl chloride with guanidine. Benzylguanidine has shown promising activity as a selective inhibitor of the enzyme O6-alkylguanine-DNA alkyltransferase (AGT), which is involved in DNA repair. This inhibitory property makes benzylguanidine a potential therapeutic agent for treating cancer, particularly for tumors that are resistant to chemotherapy. Its ability to bind to AGT and inhibit its function has also been exploited in the development of novel drug delivery systems. The compound is studied extensively to understand its pharmacological properties, including its mechanism of action, bioavailability, and potential side effects. This knowledge is crucial for developing safe and effective therapeutic strategies based on benzylguanidine.'

Cross-References

ID SourceID
PubMed CID16644
CHEMBL ID288640
SCHEMBL ID45768
MeSH IDM0302324

Synonyms (36)

Synonym
1-benzylguanidine
2211-57-6
n-benzoguanidine
guanidine, benzyl-
benzylguanidine
nsc227970
n-benzylguanidine
guanidine, (phenylmethyl)-
nsc-227970
nsc 227970
STK501305
AKOS000321591
CHEMBL288640 ,
n-benzyl-guanidine
2-benzylguanidine
bdbm50013044
1-benzyl-guanidine
n-benzylguanidinium acetate
g6537f6gqs ,
unii-g6537f6gqs
S12114
SCHEMBL45768
ABSNGNUGFQIDDO-UHFFFAOYSA-N
monobenzylguanidine
AS-54562
DTXSID20944755
guanidine,n-(phenylmethyl)-;1-benzylguanidine;n-benzylguanidine;benzylguanidine
BCP31403
BB 0323264
A878708
benzylguanidinesulfate(2:1)
n-benzylguanidineacetate
CS-0139507
EN300-73529
mfcd00461648
SY074251
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3BMus musculus (house mouse)Ki0.00100.00130.26351.4300AID6020
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID304711Antiproliferative activity against human PC3 cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID304708Antiproliferative activity against human BT474 cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID1656186Drug uptake in human SK-N-FI cells using Cy7-labeled compound incubated for 4 hrs by confocal microscopy2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
AID304718Binding affinity to calf thymus dodecamer DNA assessed as thermal stability in cacodylate buffer at 12 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352979Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.5 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID304707Antiproliferative activity against human SKBR3 cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352948Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.40 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID230956Ratio of the concentration levels determined for the adrenal medulla to the liver after 72 hr; [Adrenal Medulla] / [liver]1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID352975Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.60 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352976Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.72 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352956Hypoglycemic activity in lean normal BALB/c mouse assessed as blood glucose level at 0.54 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352977Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.54 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352938Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.57 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID304717Binding affinity to calf thymus DNA assessed as thermal stability in BPE buffer at 2 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID15565Distribution in dog adrenal medulla 30 min after administration.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID374709Hypoglycemic activity in high fat diet-induced obese BALB/c mouse model assessed as blood glucose level at 0.43 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352936Toxicity in lean normal BALB/c mouse assessed as overt signs of behavioural changes at equimolar dose of 0.5 mmol/kg galegine administered daily through diet for 7 days2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352972Antiobesity activity in lean normal BALB/c mouse assessed as change in average daily weight at 0.54 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352961Antiobesity activity in lean normal BALB/c mouse assessed as change in average daily food intake at 0.54 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID352937Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.51 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID304715Increase in caspase 3 activation in human SKBR3 cells at 20 uM after 24 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352984Antiobesity activity in ob/ob mouse model assessed as change in average daily weight at 0.26 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID374697Hypoglycemic activity in ob/ob mouse model assessed as blood glucose level at 0.26 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID1656185Antitumor activity against human SK-N-FI cells xenografted in Ncr nude mouse assessed as inhibition of tumor growth by measuring suppression of tumor weight at 3 mg/kg, sc dosed daily for 15 days relative to control2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
AID352978Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.62 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID304712Antiproliferative activity against human HT29 cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352940Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.59 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID15566Distribution in dog adrenal medulla 72 hours after administration.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID304710Antiproliferative activity against human LnCAP cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352987Antiobesity activity in ob/ob mouse model assessed as change in average daily food intake at 0.26 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID304719Binding affinity to calf thymus dodecamer DNA assessed as thermal stability in cacodylate buffer containing 0.1 M NaCl at 12 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID304709Antiproliferative activity against human T47D cells after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID304716Increase in caspase 7 activation in human SKBR3 cells at 20 uM after 24 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID352939Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.70 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID374712Metabolic stability in ob/ob mouse liver microsomes assessed as oxidative hydroxylation at 50 uM after 45 mins by HPLC-MS analysis2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID374705Antiobesity activity in high fat diet-induced obese BALB/c mouse model assessed as change in average daily food intake at 0.43 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID6020In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
An initial three-component pharmacophore for specific serotonin-3 receptor ligands.
AID352941Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.52 mmol/kg/day administered through diet for 7 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
AID374701Antiobesity activity in high fat diet-induced obese BALB/c mouse model assessed as change in average daily body weight at 0.43 mmol/kg/day administered through diet for 28 days relative to time-matched control2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Benzylguanidines and other galegine analogues inducing weight loss in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's2 (7.69)18.2507
2000's6 (23.08)29.6817
2010's12 (46.15)24.3611
2020's5 (19.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies1 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-aminobenzamide
[no description available]		2.0510benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
arcaine
arcaine: RN given refers to parent cpd; structure. 1,4-diguanidinobutane : A guanidine derivative consisting of butane having guanidino groups at the 1- and 4-positions.		2.0510guanidines
bisbenzimidazole
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.		2.0310bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
busulfan
[no description available]		7.110methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.0110N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		210aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		2.0510carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		1.9610azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		1.9610carboxamidine;
guanidines;
one-carbon compound
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		1.9710carbazoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		210mitomycinalkylating agent;
antineoplastic agent
galactose
galactopyranose : The pyranose form of galactose.		7.2510D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		210ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
bromoethane
bromoethane : A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses.		2.0310bromoalkane;
bromohydrocarbon;
volatile organic compound		alkylating agent;
carcinogenic agent;
local anaesthetic;
refrigerant;
solvent
benzylamine
aminotoluene : Any member of the class of toluenes carrying one or more amino groups.		2.0310aralkylamine;
primary amine		allergen;
EC 3.5.5.1 (nitrilase) inhibitor;
plant metabolite
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.0510biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
galegine
galegine: structure given in first source; from Verbesina encelioides and Gelega oficinalis plants; toxic to livestock		7.0510guanidines
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		210aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
technetium
Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.		2.110manganese group element atom
terbium
Terbium: An element of the rare earth family of metals. It has the atomic symbol Tb, atomic number 65, and atomic weight 158.92.		2.1110f-block element atom;
lanthanoid atom
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		7.3110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
3-iodobenzylguanidine
3-Iodobenzylguanidine: A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.		2.9340organoiodine compound
tetraiodothyroacetic acid
tetraiodothyroacetic acid: RN given refers to parent cpd; structure. 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.		2.25102-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid		apoptosis inducer;
human metabolite;
thyroid hormone
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		3.23102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
zacopride
[no description available]		1.9710benzamides
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.0510
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		2.1510macrolide lactambacterial metabolite;
immunosuppressive agent
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		210L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		1.9710indolyl carboxylic acid
1-pyrenemethylamine
[no description available]		2.0310
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		2.1510antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		210
chitosan
[no description available]		7.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Adrenal Cancer
[description not available]		01.9610
Weight Reduction
[description not available]		02.0510
Weight Loss
Decrease in existing BODY WEIGHT.		07.0510
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.2510
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		03.1440
Local Neoplasm Recurrence
[description not available]		02.610
Benign Neoplasms
[description not available]		02.4720
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4720
Cacosmia
[description not available]		04.9640
ANS (Autonomic Nervous System) Diseases
[description not available]		04.9640
Idiopathic Parkinson Disease
[description not available]		05.1350
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		04.9640
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		05.1350
Cardiac Failure
[description not available]		03.0410
Atrioventricular Nodal Re-Entrant Tachycardia
[description not available]		03.0410
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		03.0410
Tachycardia, Ventricular
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).		03.0410
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.0110
Malignant Melanoma
[description not available]		02.0110
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.0110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.0110
Leukemia L 1210
[description not available]		0210
Di Guglielmo Disease
[description not available]		02.0110
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		02.0110